To include your compound in the COVID-19 Resource Center, submit it here.

Arena's S1PR1 agonist meets in Phase II for UC

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS trial to treat ulcerative colitis. The company, which announced the news after market hours on Monday,

Read the full 357 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE